The National Research Council of Canada (NRC) and KalGene Pharmaceuticals are proud to announce an agreement to co-develop a new treatment against aggressive brain cancers.
By combining their research, NRC and KalGene are targeting glioblastomas, which are severe brain tumours associated with a median patient survival of about 15 months. The collaboration couples KalGene’s proprietary therapeutic antibody with NRC’s single domain antibodies to enable delivery inside the brain, a promising strategy that may lead to improved outcomes for patients. Acting as carriers, NRC’s antibodies will shuttle KalGene’s antibody across the challenging blood-brain barrier to target the tumour cells in the brain.
Media Relations Team
National Research Council of Canada
Telephone: 613-991-1431
Toll-free: 1-855-282-1637 (24/7)
Email: media@nrc-cnrc.gc.ca
Twitter: @nrc_cnrc
Dr.T. Nathan Yoganathan
President and CEO
KalGene Pharmaceuticals
604-375-4519
nathan@kalgene.com
